Publications
Preprints and pre-reviewed scientific papers about SARS-COV-2 seroprevalence studies.
First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS)
The global SARS-CoV-2 (COVID-19) pandemic has caused substantial worldwide mortality.
SEROPREVALENCE AND CLINICAL SPECTRUM OF SARS-CoV-2 INFECTION IN THE FIRST VERSUS THIRD TRIMESTER OF PREGNANCY
Case registries of pregnant women diagnosed with coronavirus disease (COVID-19) by polymerase chain reaction (PCR) have reported that the majority experienced mild infection, but up to 9% may require critical care.
Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China
The seroprevalence of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be a more reliable approach to detect true infected population, particularly in asymptomatic persons.
Seroprevalence of Antibodies to SARS-CoV-2 in Healthcare Workers in Non-epidemic Region: A Report from Iwate Prefecture in Japan
As of June 18, 2020, Iwate is the only one of 47 prefectures in Japan with no confirmed coronavirus disease 2019 (COVID-19) cases.
SARS-CoV-2 Community Transmission During Shelter-in-Place in San Francisco
We characterized SARS-CoV-2 infections in a densely-populated, majority Latinx San Francisco community six-weeks into the city’s shelter-in-place order.
Seroprevalence against COVID-19 and follow-up of suspected cases in primary health care in Spain
During the coronavirus disease 2019 (COVID-19) pandemic little information has been available about patients with mild or moderate symptoms attended and followed in the primary care setting, most of whom had an unknown status for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
A population-based study of the prevalence of COVID-19 infection in Espirito Santo, Brazil: methodology and results of the first stage
COVID-19 is affecting almost the entire world, causing more than four hundred thousand deaths and undermining the health care systems, as much as the economy, of the afflicted countries.
Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan -implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
It is to be determined whether people infected with SARS-CoV-2 will develop long-term immunity against SARS-CoV-2 and retain long-lasting protective antibodies after the infection is resolved.
Assessment of spread of SARS-CoV-2 by RT-PCR and concomitant serology in children in a region heavily affected by COVID-19 pandemic
Several studies indicated that children seem to be less frequently infected with SARS-CoV-2 and potentially less contagious.
Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland
The infection fatality risk (IFR) is the average number of deaths per infection by a pathogen and is key to characterizing the severity of infection across the population and for specific demographic groups.
Antibody response to infectious diseases and other factors accurately predict COVID-19 infection and severity risk 10-14 years later: a retrospective UK Biobank cohort study
Several risk factors have emerged for novel 2019 coronavirus disease (COVID-19) infection and severity.
Serological Analysis of New York City COVID19 Convalescent Plasma Donors
The development of neutralizing antibodies (NAbs) against SARS-CoV-2, following infection or vaccination, is likely to be critical for the development of sufficient population immunity to drive cessation of the COVID19 pandemic.
Overview of SARS-COV-2 studies seroprevalence in context of the worldwide COVID-19 pandemie. You can register a study here: Contribute
serohub@helmholtz-hzi.de
@serohub on Twitter
hzi-braunschweig/serohub on GitHub